Copyright
©The Author(s) 2023.
World J Gastrointest Oncol. Sep 15, 2023; 15(9): 1505-1519
Published online Sep 15, 2023. doi: 10.4251/wjgo.v15.i9.1505
Published online Sep 15, 2023. doi: 10.4251/wjgo.v15.i9.1505
Figure 1 Comprehensive visualization showcasing interaction between epigenetic pathways and probable drug treatments concerning pancreatic cancer.
EGF: Epidermal growth factor; Ras/Raf/MEK/ERK: Rat sarcoma virus/Rapidly Accelerated Fibrosarcoma/Mitogen-activated protein kinase/extracellular-signal-regulated kinase; PI3K/AKT/mTOR: Phosphoinositide 3-kinases/Ak strain transforming/Mammalian target of rapamycin; Wnt: Wingless-related integration site; PDGF: Platelet-derived growth factor; SCF/c-Kit: Stem cell factor/receptor tyrosine kinase; ALK: Anaplastic lymphoma kinase; TGF-β: Transforming growth factor beta; HGF: Hepatocyte growth factor; JAK/STAT: Janus kinase/signal transducers and activators of transcription; BTK: Bruton tyrosine kinase; Src: Tyrosine-protein kinase (sarcoma); COX-2: Cyclooxygenase 2; NRF2: Nuclear factor erythroid 2–related factor 2; HIF-1: Hypoxia-inducible factor-1; PKCδ-PKD1: Protein Kinase Cδ-Polycystin 1, Transient Receptor Potential Channel Interacting; IGF: Insulin like growth factor; VEGF: Vascular endothelial growth factor.
- Citation: Bararia A, Das A, Mitra S, Banerjee S, Chatterjee A, Sikdar N. Deoxyribonucleic acid methylation driven aberrations in pancreatic cancer-related pathways. World J Gastrointest Oncol 2023; 15(9): 1505-1519
- URL: https://www.wjgnet.com/1948-5204/full/v15/i9/1505.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v15.i9.1505